Johnson & Johnson (JNJ.N) is expected to miss its COVID-19 vaccine supply target to the European Union for the second quarter after millions of doses were banned for use in Europe over safety concerns, an EU Commission spokesman said.

The setback could cause new delays to the bloc’s vaccination drive, although the EU is relying mostly on the Pfizer-BioNTech (PFE.N), (22UAy.DE) shot to inoculate its population. More than half of adults in the EU have received at least one shot.

The European Medicines Agency (EMA) last week said J&J doses sent to Europe from an Emergent (EBS.N) factory in the United States would not be used as a precaution after a case of contamination with substances used for AstraZeneca (AZN.L) shots, which are also manufactured in that factory.


Back to Latest